The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...
Inventory in the channel decreased by approximately $2.3 million during the quarter. ARISTADA i Revenues for the quarter were $78.9 million. Inventory in the channel decreased by approximately $3.6 ...
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and ...